Journal article
Epidemiology and survival outcomes of colorectal mixed neuroendocrine-non-neuroendocrine neoplasms and neuroendocrine carcinoma
Surgery, Vol.175(3), pp.735-742
03/2024
DOI: 10.1016/j.surg.2023.09.019
PMID: 37867105
Abstract
Mixed neuroendocrine-non-neuroendocrine neoplasms are a rare subtype of neuroendocrine neoplasm consisting of ≥30% each of neuroendocrine and non-neuroendocrine differentiation. Neuroendocrine carcinomas are poorly differentiated neuroendocrine tumors. The epidemiology and prognosis of colorectal mixed neuroendocrine-non-neuroendocrine neoplasms and neuroendocrine carcinomas are not clearly defined in the literature. We sought to examine the presentation, patterns of care, and outcomes of patients with mixed neuroendocrine-non-neuroendocrine neoplasms and neuroendocrine carcinomas.
We identified patients diagnosed with stage I-III colorectal (excluding appendix) mixed neuroendocrine-non-neuroendocrine neoplasms or neuroendocrine carcinomas with only one-lifetime cancer diagnosis who underwent surgical resection between 2010 and 2018 from the National Cancer Database. We performed bidirectional selection to identify variables to include in a multivariable Cox proportional hazards model.
We identified 189 patients with a diagnosis of stage I to III colorectal mixed neuroendocrine-non-neuroendocrine neoplasms, 66% of whom had poorly differentiated tumors and 482 with neuroendocrine carcinomas. Among patients with stage III disease, 68% of patients with mixed neuroendocrine-non-neuroendocrine neoplasms and 54% of patients with neuroendocrine carcinomas received adjuvant chemotherapy. The median survival for the overall patients with mixed neuroendocrine-non-neuroendocrine neoplasms and neuroendocrine carcinomas cohorts were 38 and 42 months, respectively (P = .22), and the median survival for patients with mixed neuroendocrine-non-neuroendocrine neoplasms and neuroendocrine carcinomas with stage III disease were 30 and 25 months, respectively (P = .27). In multivariable analysis, fewer number of positive nodes and receipt of adjuvant chemotherapy were independently associated with decreased risk of mortality for patients with mixed neuroendocrine-non-neuroendocrine neoplasms and neuroendocrine carcinomas.
Adjuvant chemotherapy is associated with improved survival in stage III mixed neuroendocrine-non-neuroendocrine neoplasms and neuroendocrine carcinomas. Future studies are warranted to identify subsets of patients benefiting most from adjuvant therapy.
Details
- Title: Subtitle
- Epidemiology and survival outcomes of colorectal mixed neuroendocrine-non-neuroendocrine neoplasms and neuroendocrine carcinoma
- Creators
- Mohammed O Suraju - University of IowaKyle Freischlag - Department of Surgery, University of Iowa Carver College of Medicine, Iowa City, IADenise Jacob - Albert Einstein College of MedicineDakota Thompson - University of IowaAndrew Mckeen - Carver College of Medicine, University of Iowa, Iowa City, IACatherine Tran - University of IowaScott K Sherman - University of IowaPaolo Goffredo - University of MinnesotaRonald J Weigel - University of IowaImran Hassan
- Resource Type
- Journal article
- Publication Details
- Surgery, Vol.175(3), pp.735-742
- DOI
- 10.1016/j.surg.2023.09.019
- PMID
- 37867105
- eISSN
- 1532-7361
- Language
- English
- Date published
- 03/2024
- Academic Unit
- Molecular Physiology and Biophysics; Anatomy and Cell Biology; Orthopedics and Rehabilitation; Surgery; Biochemistry and Molecular Biology
- Record Identifier
- 9984555558902771
Metrics
5 Record Views